Back

Braveheart Bio initiates Phase 3 LIONHEART-HCM trial, reports $527.3M pro forma cash

Verifying
  • Braveheart Bio initiated the Phase 3 LIONHEART-HCM trial for BHB-1893 in symptomatic obstructive HCM.
  • $527.3 million was the company’s pro forma cash balance after August IPO proceeds.
  • Braveheart Bio expects an interim LIONHEART-HCM analysis in the second half of 2027.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.